FDA Approves Novartis’ Cosentyx for Axial Spondyloarthritis

Novartis’ Cosentyx (secukinumab) has been granted FDA approval for treatment of non-radiographic axial spondyloarthritis (nr-axSpA), a form of arthritis that can cause inflammation on the spine.

The approval was based on the results of a phase 3 trial in which Cosentyx, a human monoclonal antibody, demonstrated significant improvements vs. a placebo.

The European Medicines Agency had approved Cosentyx for the same indication in April.